EYA1 and otofaciocervical syndrome 1: Heterozygous variants in EYA1 (EYA transcriptional coactivator and phosphatase 1) account for approximately 40–75% of individuals clinically diagnosed with BORSD [11,12], but have also been reported in OTFCS patients [13,14,15].